PCV22 Estimating the Reduction in Medical Care Costs Associated with Ticagrelor and Aspirin in Patients with Acute Ischemic Stroke or TIA

The efficacy of ticagrelor 90mg and aspirin (ticagrelor-aspirin) for the prevention of stroke following an ischaemic stroke (IS) or transient ischaemic attack (TIA) was evaluated in the Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death (THALES, NCT03354429) trial. Ticagrelor-aspirin resulted in a 17% reduction in the risk of stroke or death over 30 days versus aspirin, but with more bleeding events. Ticagrelor 90mg is approved to reduce stroke risk in patients with acute IS (NIH Stroke Scale score ≤5) or high-risk TIA by the Food and Drug Administration.

Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: P. McEwan, O. Darlington, M. Knutsson, H. Denison, P. Ladenvall, P. Amarenco, S.C. Johnston, S. Evans, S. James, A. Himmelmann, J. Venditto, C. Mellstrom, N. Atreja, A. Tank Source Type: research